Novo Nordisk Investor Presentation 2023 ADA San Diego

Novo Nordisk presented Q1 2023 results and strategic aspirations at the ADA San Diego conference on June 25, 2023. The presentation highlights commercial execution with 25% sales growth, obesity care sales of DKK 7.8 billion, and innovation progress including regulatory submissions for diabetes and obesity treatments. The company emphasizes its commitment to reaching millions of diabetes patients worldwide while advancing sustainable operations and leadership diversity.